ClinicalTrials.gg
Active, not recruitingNCT05821530Updated Jun 8, 2023

HFIT Versus TENS Study for Chronic Low Back and Knee Pain

An interventional study of HFIT and TENS in Chronic Pain, Knee Pain Chronic and Back Pain, Low, sponsored by Hinge Health, Inc. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Hinge Health, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
113th of 1,092
325 · median 60
Started
2023
with 116 others
No phase
803 of 1,283
168 open now
Primary completion
2023-06
later than 4 of 347 live
Registered
963rd of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 113th largest by enrollment of the 1,092 interventional ones that give a count, is one of 117 that started in 2023, is one of 803 with no phase, reaches primary completion later than 4 of the 347 other live ones, and was the 963rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

A high-frequency impulse therapy (HFIT) device (Enso, San Francisco, CA) is a portable device for the treatment of musculoskeletal pain. This three-arm randomized controlled trial study compares a HFIT group to a standard transcutaneous electrical nerve stimulator (TENS) group and a control group.

03

Conditions studied

  • Chronic Pain
  • Knee Pain Chronic
  • Back Pain, Low

Keywords

  • musculoskeletal
  • chronic
  • pain
  • knee pain
  • back pain
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or over and under age 65
  • Baseline pain is 40 or more out of 100 on a NPRS
  • Member of digital MSK program's chronic back or knee pain program, after January 1, 2023
  • Member engaged in the most recent 3 weeks
  • Experiencing chronic pain for at least 3 months
  • Subject able to understand and provide
  • Has an email account

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of cancer/malignant tumors in the last 5 years
  • Back or knee surgery in the last 6 months
  • Has a cardiac pacemaker, implanted defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other implanted electronic device
  • Patients with history of opioid, alcohol, or drug abuse in the last 1 year
  • Cognitive, behavioral, neurologic, or psychiatric disorder (e.g., dementia, Parkinson's, schizophrenia, stroke) that may interfere with the study or prevent the subject from complying with the requirements of the protocol
  • Pregnant or plan on becoming pregnant in the next year
  • Have epilepsy
  • Have cardiovascular disease
  • Current pain (in the past 24 hours) is less than 40 out of 100 on a NPRS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    HFIT

    Participants received a HFIT device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the HFIT device for at least 1 hour daily for 4 weeks.

    Device: HFIT

  • Experimental
    TENS

    Participants received a TENS device to treat their chronic pain and took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists. Participants were encouraged to use the TENS device for at least 1 hour daily for 4 weeks.

    Device: TENS

  • Active comparator
    Control

    Participants took part in a digital MSK program, which provided customized exercise therapy sessions, educational articles, and access to coaches and physical therapists.

    Other: Control

Interventions

  • DeviceHFIT

    At least 1 hour daily for 4 weeks

    Also known as: Enso

  • DeviceTENS

    At least 1 hour daily for 4 weeks

  • OtherControl

    Users will continue to use the digital MSK program as needed

    Also known as: Digital MSK program

06

What researchers measure

Primary outcomes

  1. Pain MCID

    Pain will be measured by the Numeric Pain Rating Scale, ranging from 0 (no pain) to 100 (worst possible pain). The minimal clinically important difference (MCID) of pain will be achieved (0/1) if there is at least a 34% or 23 point improvement, as based on literature.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Function MCID (Back)

    Back function will be measured by the Roland-Morris Disability Questionnaire 11-item (RMDQ-11, 0-100, higher indicates worse function) scores for back users. Function MCID will be achieved (0/1) if there is at least a 30% improvement in RMDQ-11, as based on literature.

    Time frame: Baseline and Week 4

  2. Function MCID (Knee)

    Knee function will be measured by the Knee Injury and Osteoarthritis Outcome Score - Physical Short Form (KOOS-PS, 0-100, higher indicates worse function). Function MCID will be achieved (0/1) if there is at least an 8 point improvement in KOOS-PS, as based on literature.

    Time frame: Baseline and Week 4

  3. Anxiety

    Anxiety will be assessed by the Generalized Anxiety Disorder 2-item (GAD-2, 0-6, higher is worse) scores. A score of 3 or higher is defined as screening in for having anxiety, based on literature. The percentage of users who screen in for anxiety in each group will be compared.

    Time frame: Baseline and Week 4

  4. Depression

    Depression will be assessed by the Patient Health Questionnaire 2-item (PHQ-2, 0-6, higher is worse) scores. A score of 3 or higher is defined as screening in for having depression, based on literature. The percentage of users who screen in for depression in each group will be compared.

    Time frame: Baseline and Week 4

  5. Opioid use

    Opioid use data will be collected through survey questions. The percentage of users who use opioids in each group during the study will be compared.

    Time frame: Baseline and Week 4

07

Study locations

1 site
  • Hinge Health, Inc
    San Francisco, California 94105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2023, 2 months after the start.

Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 20, 2023
StartActual
Apr 24, 2023
Primary completionEst.
Jun 30, 2023
CompletionEst.
Jun 30, 2023
Last update
Jun 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05821530
Lead sponsor
Hinge Health, Inc
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
Apr 24, 2023
Primary completion
Jun 30, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Jun 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion